Data / Drug companies / Exela Pharma Sciences, LLC
Exela Pharma Sciences, LLC: 25 products in the FDA NDC directory, labeler code 51754
Exela Pharma Sciences, LLC (labeler code 51754) lists 25 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 25 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on December 12, 2023.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51754
- Products in commercial distribution
- 25
- Packages
- 32
- Finished drugs by generic name
- 12
- Prescription products
- 25
- Over the counter products
- 0
- Flagged as original packager
- 25 of 25 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- September 21, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 14 | 56% |
| Generic drugs (ANDA) | 11 | 44% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 25 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Sodium bicarbonate | 6 | 51 |
| Glycopyrrolate | 4 | 64 |
| Caffeine citrate | 2 | 8 |
| Verapamil hydrochloride | 2 | 46 |
| Cysteine hydrochloride | 2 | 2 |
| Ephedrine sulfate | 2 | 26 |
| Sodium nitroprusside | 2 | 14 |
| Tranexamic acid | 1 | 39 |
| Cupric chloride | 1 | 7 |
| Zinc chloride | 1 | 3 |
| Neostigmine methylsulfate | 1 | 24 |
| Potassium acetate | 1 | 3 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 16 | 64% |
| Injection | 8 | 32% |
| Solution | 1 | 4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Elcys | 51754-1008 | Injection, solution | New drug applications (NDA) | December 12, 2023 |
| Bloxiverz | 51754-1200 | Injection | New drug applications (NDA) | November 6, 2023 |
| Potassium Acetate | 51754-2004 | Injection | Generic drugs (ANDA) | August 1, 2023 |
| Cupric chloride | 51754-0103 | Injection, solution | Generic drugs (ANDA) | February 1, 2023 |
| Zinc Chloride | 51754-0102 | Injection | Generic drugs (ANDA) | August 27, 2021 |
| Akovaz | 51754-4250 | Injection | New drug applications (NDA) | May 10, 2021 |
| Akovaz | 51754-4200 | Injection | New drug applications (NDA) | April 15, 2021 |
| Sodium Bicarbonate | 51754-5011 | Injection, solution | Generic drugs (ANDA) | September 1, 2020 |
| Sodium Bicarbonate | 51754-5002 | Injection, solution | Generic drugs (ANDA) | September 1, 2020 |
| Glyrx-pf | 51754-6015 | Injection, solution | New drug applications (NDA) | June 1, 2020 |
| Glyrx-pf | 51754-6013 | Injection, solution | New drug applications (NDA) | June 1, 2020 |
| Sodium Bicarbonate | 51754-8888 | Injection, solution | Generic drugs (ANDA) | August 1, 2019 |
| Sodium Bicarbonate | 51754-8020 | Injection, solution | Generic drugs (ANDA) | August 1, 2019 |
| Sodium Bicarbonate | 51754-5001 | Injection, solution | Generic drugs (ANDA) | August 1, 2019 |
| Tranexamic acid in sodium chloride | 51754-0108 | Injection, solution | New drug applications (NDA) | June 1, 2019 |
| Elcys | 51754-1007 | Injection, solution | New drug applications (NDA) | May 28, 2019 |
| Sodium Bicarbonate | 51754-5012 | Injection, solution | Generic drugs (ANDA) | September 27, 2018 |
| Glyrx-pf | 51754-6001 | Injection, solution | New drug applications (NDA) | August 1, 2018 |
| Glyrx-pf | 51754-6000 | Injection, solution | New drug applications (NDA) | August 1, 2018 |
| Nipride rtu | 51754-1029 | Injection, solution | New drug applications (NDA) | July 20, 2018 |
| Nipride rtu | 51754-1006 | Injection, solution | New drug applications (NDA) | March 20, 2017 |
| Verapamil Hydrochloride | 51754-0204 | Injection | New drug applications (NDA) | February 1, 2017 |
| Verapamil Hydrochloride | 51754-0203 | Injection | New drug applications (NDA) | April 22, 2016 |
| Caffeine citrate | 51754-0500 | Injection | Generic drugs (ANDA) | March 30, 2015 |
| Caffeine citrate | 51754-0501 | Solution | Generic drugs (ANDA) | September 21, 2006 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.